Egbert F. Smit, MD, PhD, on Clinical Implications of Fam-trastuzumab Deruxtecan in HER2-Mutated Metastatic NSCLC

Posted: Monday, July 13, 2020

Egbert F. Smit, MD, PhD, of the Netherlands Cancer Institute, discusses the DESTINY-Lung01 study, its data on response rates with fam-trastuzumab deruxtecan, the frequent grade 3+ treatment-related adverse events, and how well tolerated this type of regimen might be in clinical practice.